A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Inclusion Criteria: * Male and female patients with a confirmed diagnosis of vitiligo on the face and with T-VASI range 0.5-50% * Stable face vitiligo with F-VASI of at least 0.1% * Stable or slowly progressive vitiligo over a 3-month period * Fitzpatrick skin types IV-VI * Treatment with narrowband (NB)-UVB light 2-3 times per week during the last four weeks preceding the first implant for priming Exclusion Criteria: * Patients with segmental vitiligo * Fitzpatrick skin types I-III * Treatment with NB-UVB phototherapy in the last three months prior to phototherapy, excluding the sessions for priming in the four weeks prior to treatment. A 3-month washout period from phototherapy is necessary prior to priming. * Previous topical treatment for vitiligo * Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant * History of melanoma or lentigo maligna * Any current skin disease that may interfere with the study evaluation * Presence of severe hepatic disease or hepatic impairment * Renal impairment * History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation * Female who is pregnant or lactating * Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter * Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above * Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit * Use of any other prior and concomitant therapy which may interfere with the objective of the study * Subjects assessed as not suitable for the study in the opinion of the Investigator